Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy

Cancer Discovery

Volumn 4, Issue 5, 2014, Pages 527-537

  Tan, David S P ^a   Bedard, Philippe L ^a   Kuruvilla, John ^a   Siu, Lillian L ^a   Razak, Albiruni R Abdul ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANTINEOPLASTIC AGENT; APC PROTEIN; BCR ABL PROTEIN; BRCA1 PROTEIN; CBS 9106; CYCLIN DEPENDENT KINASE 2; DNA TOPOISOMERASE; ESTROGEN RECEPTOR ALPHA; EXPORTIN 1; FIRTECAN; FOCAL ADHESION KINASE; GALECTIN 3; IMATINIB; KARYOPHERIN BETA; KOS 2464; KPT 115; KPT 127; KPT 185; KPT 251; KPT 276; LEPTOMYCIN B; NUCLEOPHOSMIN; NUCLEOPORIN; PKF 050 638; PROTEIN P27; PROTEIN P53; SELECTIVE INHIBITORS OF NUCLEAR EXPORT; SELINEXOR; SURVIVIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERDINEXOR; CELL RECEPTOR; EXPORTIN 1 PROTEIN; KARYOPHERIN;

ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; DNA DAMAGE; HUMAN; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR PORE; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ACTIVE TRANSPORT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASMS; SHORT INTERSPERSED REPEAT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KARYOPHERINS; NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SHORT INTERSPERSED NUCLEOTIDE ELEMENTS;

EID: 84899671107     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-1005     Document Type: Review

References (88)

1. Zaidi SK, Young DW, Javed A, Pratap J, Montecino M, van Wijnen A, et al. Nuclear microenvironments in biological control and cancer. Nat Rev Cancer 2007; 7: 454-63.
2. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-32.
3. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004; 4: 106-17.
4. Cook A, Bono F, Jinek M, Conti E. Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 2007; 76: 647-71.
5. Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem 2007; 282: 5101-5.
6. Lee BJ, Cansizoglu AE, Suel KE, Louis TH, Zhang Z, Chook YM. Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell 2006; 126: 543-58.
7. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H, et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458: 1136-41.
8. Kutay U, Guttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005; 15: 121-4.
9. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr Opin Struct Biol 2010; 20: 782-90.
10. Kao HY. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem 2001; 276: 47496-507.
11. Yang JY, Hung MC. A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res 2009; 15: 752-7.
12. Bischoff FR, Klebe C, Kretschmer J, Wittinghofer A, Ponstingl H. RanGAP1 induces GTPase activity of nuclear Ras-related Ran. Proc Natl Acad Sci U S A 1994; 91: 2587-91.
13. Izaurralde E, Kutay U, von Kobbe C, Mattaj IW, Gorlich D. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J 1997; 16: 6535-47.
14. Marelli M, Dilworth DJ, Wozniak RW, Aitchison JD. The dynamics of karyopherin-mediated nuclear transport. Biochem Cell Biol 2001; 79: 603-12.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
16. Kancha RK, von Bubnoff N, Miething C, Peschel C, Gotze KS, Duyster J. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica 2008; 93: 1718-22.
17. Goh YM, Cinghu S, Hong ET, Lee YS, Kim JH, Jang JW, et al. Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm. J Biol Chem 2010; 285: 10122-9.
18. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117: 225-37.
19. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005; 65: 7743-50.
20. Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 2008; 68: 9404-12.
21. Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009; 69: 6899-905.
22. Noske A, Weichert W, Niesporek S, Röske A, Buckendahl A-C, Koch I, et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008; 112: 1733-43.
23. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009; 32: E315.
24. Lesinski GB, Yang J, Bill MA, Landesman Y, Shacham S, Kauffman M, et al. Effect of small inhibitors of nuclear export (SINE) on growth inhibition and apoptosis of human melanoma cells. J Clin Oncol 30, 2012 (suppl; abstr e13549).
25. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009; 65: 153-9.
26. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009; 124: 1829-40.
27. Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Chen P, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009; 21: 229-35.
28. van der Watt PJ, Leaner VD. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 2011; 1809: 316-26.
29. Nguyen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012; 3: 137-51.
30. Thakar K, Karaca S, Port SA, Urlaub H, Kehlenbach RH. Identification of CRM1-dependent nuclear export cargos using quantitative mass spectrometry. Mol Cell Proteomics 2013; 12: 664-78.
31. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62.
32. Khanna A, Pimanda JE, Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Cancer Res 2013; 73: 6548-53.
33. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011; 105: 989-95.
34. Arnaoutov A, Azuma Y, Ribbeck K, Joseph J, Boyarchuk Y, Karpova T, et al. Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol 2005; 7: 626-32. 35.
35. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-83.
36. Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 2011; 110: 107-39.
37. Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A 2008; 105: 16958-63.
38. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998; 18: 7288-93.
39. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999; 18: 1660-72.
40. O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat 2003; 6: 313-22.
41. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-5.
42. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412.
43. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002; 8: 1076-8.
44. Vogt PK, Jiang H, Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005; 4: 908-13.
45. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010; 16: 4325-30.
46. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-83.
47. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000; 20: 8969-82.
48. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/ Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-52.
49. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-67.
50. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006; 20: 47-64.
51. Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 2002; 277: 28706-13.
52. Wang Y, Xiang J, Ji F, Deng Y, Tang C, Yang S, et al. Knockdown of CRM1 inhibits the nuclear export of p27(Kip1) phosphorylated at serine 10 and plays a role in the pathogenesis of epithelial ovarian cancer. Cancer Lett 2014; 343: 6-13.
53. Feng Z, Kachnic L, Zhang J, Powell SN, Xia F. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 2004; 279: 28574-84.
54. Brodie KM, Henderson BR. Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. J Biol Chem 2012; 287: 7701-16.
55. Jia Y, Song W, Zhang F, Yan J, Yang Q. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway. Oncogene 2013; 32: 1943-9.
56. Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, de Falco A, et al. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 2012; 31: 4868-77.
57. Lombardi M, Castoria G, Migliaccio A, Barone MV, Di Stasio R, Ciociola A, et al. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol 2008; 182: 327-40.
58. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, et al. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzymemediated DNA cleavage. J Biol Chem 1991; 266: 14585-92.
59. Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 1991; 30: 1807-13.
60. Fukumori T, Kanayama H, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007; 10: 101-8.
61. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim HR, et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004; 24: 4395-406.
62. Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006; 66: 3114-9.
63. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG Jr, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999; 399: 806-9.
64. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001; 7: 228-34.
65. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-9.
66. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a forkhead transcription factor in PTENdeficient tumor cells. Cancer Cell 2003; 4: 463-76.
67. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J, et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 2013; 110: 1303-8.
68. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, et al. Selective inhibitors of nuclear export (SINE) show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012; 120: 4621-34.
69. Mutka SC, Yang WQ, Dong SD, Ward SL, Craig DA, Timmermans PB, et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009; 69: 510-7.
70. Sakakibara K, Saito N, Sato T, Suzuki A, Hasegawa Y, Friedman JM, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011; 118: 3922-31.
71. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002; 99: 14440-5.
72. Azmi AS, Kauffman M, McCauley D, Shacham S, Mohammad RM. Novel small-molecule CRM-1 inhibitor for GI cancer therapy. J Clin Oncol 30, 2012 (suppl 4; abstr 245).
73. Chung HW, Salas Fragomeni RA, Shacham S, Kauffman M, Cusack JC. Effect of inhibition of nuclear protein export using a novel CRM1 inhibitor on the apoptotic response to SN38 in preclinical colon cancer models. J Clin Oncol 30, 2012 (suppl 4; abstr 609).
74. Inoue H, Kauffman M, Shacham S, Landesman Y, Weiss RH. Evaluation of selective inhibitors of nuclear export (SINE) CRM1 inhibitors for the treatment of renal cell carcinoma (RCC). J Clin Oncol 30, 2012 (suppl; abstr 4634).
75. McCauley D, Landesman Y, Senapedis W, Kashyap T, Saint-Martin J-R, Plamondon L, et al. Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). J Clin Oncol 30, 2012 (suppl; abstr 1055).
76. Shacham S, Barnard S, Kisseberth W, Ito D, Jensen K, Borgotti A, et al. Results of a phase I dose escalation study of the novel, oral CRM1 selective inhibitor of nuclear export (SINE) KPT-335 in dogs with spontaneous non-Hodgkin's lymphomas (NHL) [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Abstract nr 161.
77. Shacham S, Gravina GL, Ricevuto E, Mancini A, Chin L, Shechter S, et al. Preclinical evaluation of selective inhibitors of nuclear export (SINE) CRM1 (XPO1) inhibitors in prostate cancer (PrCa). J Clin Oncol 30, 2012 (suppl; abstr e15200).
78. Shacham S, Kauffman M, Sandanayaka V, Draetta G, Shechter S, Williams J, et al. Preclinical development of small-molecule CRM1 inhibitors as novel therapy for the treatment of colorectal cancer (CRC). J Clin Oncol 29, 2011 (suppl 4; abstr 430).
79. Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013; 27: 66-74.
80. London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, et al. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS ONE 2014; 9: e87585.
81. Razak A, Sorensen M, Mahipal M, Shacham S. First-in-class, first-inhuman phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors. J Clin Oncol 31, 2013 (suppl; abstr 2505).
82. Chen C, Gutierrez M, de Nully Brown P, Gabrail N, Baz R, Reece DE, et al. A first-in-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM). Blood 2013; 122.
83. Kuruvilla J, Gutierrez M, Shah B, Gabrail NY, de Nully Brown P, Stone RM, et al. Preliminary evidence of anti tumor activity of Selinexor (KPT-330) in a phase i trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory non Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2013; 122: 90.
84. Savona M, Garzon R, de Nully Brown P, Yee K, Lance JE, Gutierrez M, et al. Phase I trial of Selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). Blood 2013; 122: 1440.
85. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013; 122: 3034-44.
86. Abdel-Naim AB, Lu C, Shao C, Cobos E, Singh KP, Gao W. Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS ONE 2012; 7: e32895.
87. Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, et al. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 2013; 12: 1171-9.
88. Akakura S, Yoshida M, Yoneda Y, Horinouchi S. A role for Hsc70 in regulating nucleocytoplasmic transport of a temperature-sensitive p53 (p53Val-135). J Biol Chem 2001; 276: 14649-57.